TRAW · Traws Pharma, Inc. · Proposed Sales
$0.57
+0.02 (+4.25%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.66M
Shares
15.37M
Volume · Oct 2
69.63K
Avg daily vol (3M)
570.37K
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2024-03-14 | MARK GUERIN | Officer | 2,591 | 2024-03-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-03-14 | STEVEN M FRUCHTMAN | Officer, Director | 8,727 | 2024-03-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-02-08 | STEVEN M FRUCHTMAN | Officer, Director | 9,212 | 2024-02-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Showing 1–3 of 3 filings